Expect continued margin improvement aiming for 24-25% EBITDA by 2025 with reinvestment for growth. Recent isotonic acquisitions in Argentina focus on ibuprofen market. US strategy includes core categories, SKU reduction, and Hispanic brand expansion for sustained growth.